16+
Major trials tracked
Immunology & inflammation · Live ClinicalTrials.gov data
Guselkumab (Tremfya) clinical trial pipeline
The timeline below tracks the 16 largest phase 2–4 guselkumab trials on ClinicalTrials.gov by enrolment, 3 of them actively recruiting. The next phase 3 primary completion among them is expected Mar 2027. Refreshed daily — add up to four competitors to compare pipelines side by side.
9
Phase 3 trials
3
Actively recruiting
Mar 2027
Next phase 3 primary completion
6,991
Participants across trials
Janssen Research & Development, LLC
Lead sponsor by trial count
guselkumab (16)6 active2011–2033
guselkumab
'11
'13
'15
'17
'19
'21
'23
'25
'27
'29
'31
'33
guselkumab
X-PLOREP2
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate TherapyP2
VOYAGE 1P3
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)P2
An Efficacy and Safety of Guselkumab in Participants With Palmoplantar PustulosisP3
ECLIPSEP3
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic ArthritisP3
VEGAP2
QUASARP2
BeNeBioP4
SOLSTICEP3
PAMPAP4
VISIBLEP3
FUZION CDP3
TRILOGYP3
DUET ENCORE-UCP3
Upcoming readouts
4 ahead · guselkumab
Select a trial to load its full ClinicalTrials.gov record.
Key guselkumab trials
Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05004727 | PAMPA — Multi-Center PAMPA Study | Phase 4 | Recruiting | Dec 2026 |
| NCT04340076 | BeNeBio — Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis | Phase 4 | Completed | Jan 2025 |
| NCT07577856 | DUET ENCORE-UC — A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 3 | Recruiting | Aug 2028 |
| NCT06663332 | TRILOGY — A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants | Phase 3 | Recruiting | Dec 2031 |
| NCT04936308 | SOLSTICE — Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-T… | Phase 3 | Active, not recruiting | Oct 2024 |
| NCT05347095 | FUZION CD — A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | Phase 3 | Active, not recruiting | Mar 2027 |
| NCT02207231 | VOYAGE 1 — A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis | Phase 3 | Completed | Sept 2015 |
| NCT02641730 | An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis | Phase 3 | Completed | Mar 2017 |
| NCT03090100 | ECLIPSE — A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Mo… | Phase 3 | Completed | Aug 2018 |
| NCT03158285 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Acti… | Phase 3 | Completed | Feb 2019 |
| NCT05272150 | VISIBLE — Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis | Phase 3 | Completed | May 2025 |
| NCT04033445 | QUASAR — A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 2 | Active, not recruiting | Sept 2023 |
Related drug pipelines
FAQ
- How many clinical trials are running for guselkumab?
- ClinicalTrials.gov lists more than 16 phase 2–4 guselkumab trials. This page tracks the 16 largest by enrolment: 5 phase 2, 9 phase 3, and 2 phase 4 among them, with 3 actively recruiting. Updated daily.
- Where does this data come from?
- All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
- Can I compare guselkumab against other drugs?
- Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.
Join the waitlist
Be the first to access ComplyRx
We'll let you know as soon as your spot opens to use ComplyRx.
By joining, you agree to our Privacy Policy.